Pharmacokinetics and metabolism of [14C]rosaramicin in dogs. 1986

C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz

The pharmacokinetics and metabolism of [14C]rosaramicin were studied in dogs after intravenous (i.v.; 10 mg/kg [bodyweight]) and oral (25 mg/kg) administration. After i.v. administration, rosaramicin levels in plasma declined rapidly, with half-lives of 0.22 h for the distribution phase and 0.97 h for the elimination phase. The apparent volume of distribution was 3.43 liters/kg, and the total body clearance was 106 mg/min . kg, indicating extensive distribution in tissue or metabolism or both. The absorption of oral solution was 58%, and the absolute bioavailability of rosaramicin was 35%. The plasma area under the curve of unchanged rosaramicin was only 5% that of total radioactivity after oral administration and 8% after i.v. administration, indicating extensive metabolism of the drug. The total radioactivity excreted in urine accounted for only 24% of the i.v. dose and 17% of the oral dose. Fecal radioactivity accounted for 71% of the i.v. dose and 68% of the oral dose. Several metabolites were observed in the plasma and urine. The amount of unchanged rosaramicin in urine (1 to 2% of the dose) was quite small after drug administration by either route.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007933 Leucomycins An antibiotic complex produced by Streptomyces kitasatoensis. The complex consists of a mixture of at least eight biologically active components, A1 and A3 to A9. Leucomycins have both antibacterial and antimycoplasmal activities.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
January 1981, European journal of drug metabolism and pharmacokinetics,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
February 1990, Arzneimittel-Forschung,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
June 1986, The Journal of antimicrobial chemotherapy,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
January 1986, Xenobiotica; the fate of foreign compounds in biological systems,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
April 1989, Arzneimittel-Forschung,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
January 1982, Biopharmaceutics & drug disposition,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
August 2010, Drug metabolism letters,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
December 1987, Annals of allergy,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
January 1986, Drug metabolism and disposition: the biological fate of chemicals,
C C Lin, and H K Kim, and A Marco, and E Radwanski, and S Symchowicz
January 1982, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!